SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Granella F)
 

Search: WFRF:(Granella F) > Silent lesions on M...

  • Min, M (author)

Silent lesions on MRI imaging - Shifting goal posts for treatment decisions in multiple sclerosis

  • Article/chapterEnglish2018

Publisher, publication year, extent ...

  • 2018-09-20
  • SAGE Publications,2018

Numbers

  • LIBRIS-ID:oai:prod.swepub.kib.ki.se:139409519
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:139409519URI
  • https://doi.org/10.1177/1352458518798147DOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • The current best practice suggests yearly magnetic resonance imaging (MRI) to monitor treatment response in multiple sclerosis (MS) patients. Objective: To evaluate the current practice of clinicians changing MS treatment based on subclinical new MRI lesions alone. Methods: Using MSBase, an international MS patient registry with MRI data, we analysed the probability of treatment change among patients with clinically silent new MRI lesions. Results: A total of 8311 MRI brain scans of 4232 patients were identified. Around 26.9% (336/1247) MRIs with one new T2 lesion were followed by disease-modifying therapy (DMT) change, increasing to 50.2% (129/257) with six new T2 lesions. DMT change was twice as likely with new T1 contrast enhancing compared to new T2 lesions odds ratio (OR): 2.43, 95% confidence interval (CI): 2.00–2.96 vs OR: 1.26 (95% CI: 1.22–1.29). DMT change with new MRI lesions occurred most frequently with ‘injectable’ DMTs. The probability of switching therapy was greater only after high-efficacy therapies became available in 2007 (after, OR: 1.43, 95% CI: 1.28–1.59 vs before, OR: 0.98, 95% CI: 0.520–1.88). Conclusion: MS clinicians rely increasingly on MRI alone in their treatment decisions, utilizing low thresholds (1 new T2 lesion) for optimizing MS therapy. This signals a shift towards no evidence of disease activity (NEDA)-3 since high-efficacy therapies became available.

Added entries (persons, corporate bodies, meetings, titles ...)

  • Spelman, T (author)
  • Lugaresi, A (author)
  • Boz, C (author)
  • Spitaleri, DLA (author)
  • Pucci, E (author)
  • Grand'Maison, F (author)
  • Granella, F (author)
  • Izquierdo, G (author)
  • Butzkueven, H (author)
  • Sanchez-Menoyo, JL (author)
  • Barnett, M (author)
  • Girard, M (author)
  • Trojano, M (author)
  • Grammond, P (author)
  • Duquette, P (author)
  • Sola, P (author)
  • Alroughani, R (author)
  • Hupperts, R (author)
  • Vucic, S (author)
  • Kalincik, T (author)
  • Van pesch, V (author)
  • Lechner-Scott, J (author)

Related titles

  • In:Multiple sclerosis (Houndmills, Basingstoke, England): SAGE Publications24:12, s. 1569-15771477-09701352-4585

Internet link

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view